Medicamen Biotech Limited has informed the Exchange regarding Board meeting held on August 12, 2025.
MEDICAMEQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medicamen Biotech's board met on August 12, 2025 and approved unaudited financial results for Q1 FY26 (quarter ended June 30, 2025). On a standalone basis, revenue from operations came in at Rs. 38.45 crore (down from Rs. 41.48 crore in Q1 FY25), with net profit of Rs. 1.64 crore versus Rs. 2.26 crore last year, a decline of about 27%. Consolidated revenue was nearly flat at Rs. 43.04 crore with net profit of Rs. 1.60 crore (down from Rs. 1.85 crore). The auditors issued an unmodified (clean) review report. The board also approved a final dividend of Re. 1 per share (10%) for FY25, subject to shareholder approval, and the 32nd AGM is scheduled for September 26, 2025. Additionally, Mr. Ashwani Kumar Sharma was redesignated as Whole-time/Executive Director, and Mr. Sham Goel and Mr. Shaival Saurabh were appointed as new Non-Executive Independent Directors for five-year terms.
The year-on-year decline in both standalone revenue and net profit for Q1 FY26 is a mild negative signal, though consolidated results were more stable. The proposed Re. 1 final dividend and new independent director appointments are routine governance positives. Short-term stock reaction may be muted given the weak quarterly performance.